AmplifyBio, a contract research organization, completed the acquisition of Pact Pharma, a privately held biopharmaceutical company. Financial terms were not disclosed. "This deal allows PACT to retain its core intellectual property and continue our mission of developing novel, neoantigen-targeted T-Cell Therapies. At the same time, we're working with AmplifyBio to leverage our platforms to offer a unique combination of optimization, characterization, safety and efficacy services to a wider range of clients seeking to better understand the immunology of their adoptive cell therapies," Scott Garland, PACT Pharma CEO.